STING1 and sarcoma: As macrophages are highly sensitive to STING agonists (64–66) and are abundant in both human and pre-clinical sarcoma models (29, 39, 56, 67–69), we hypothesized that a reduction in tumor associated macrophages (TAMs) would mitigate the therapeutic response to STING agonism.